ClinicalTrials.gg
RecruitingNCT07093671MBT-PsychosisUpdated Jul 8, 2026

Mentalization Based Treatment (MBT) in Help Seeking Youths With a Clinical High-Risk Condition for Psychosis (CHR-P)

An interventional study of MBT + NBCI in Psychosis, sponsored by Marco Armando. Recruiting at 1 site in Switzerland. Open to participants aged 14 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Marco Armando · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
14 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Psychotic Disorders with a site in Switzerland — 10 open to participants now, 11 under way, 3 of them phase 3. Psychotic Disorders · Switzerland.

Planned enrollment
6th of 20
212 · median 100
Started
2025
with 1 other
No phase
13 of 25
6 open now
Primary completion
2028-08
later than 7 of 10 live
Registered
22nd of 25
by date

Among the 25 studies in Psychotic Disorders with a site in Switzerland, this one is the 6th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2025, is one of 13 with no phase, reaches primary completion later than 7 of the 10 other live ones, and was the 22nd registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

10 of the 25 studies in Psychotic Disorders with a site in Switzerland are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 14 Years to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Psychotic Disorders with a site in Switzerland, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of Mentalization-Based Treatment (MBT) combined with Need-Based Clinical Interventions (NBCI) compared to NBCI alone, on CHR-P diagnostic statuses and symptom expression (Hypothesis 1). Specifically, the investigator will assess diagnostic outcomes using a 3-level variable: transition to psychosis, CHR-P status quo, and remission out of CHR-P, as well as CHR-P symptom expression. The investigator hypothesize that: (1a) the experimental treatment (MBT + NBCI) will have a significant effect on diagnostic status (i.e. transition to psychosis) at the end of treatment and follow-up; (1b) the experimental treatment (MBT + NBCI) will significantly reduce the severity of psychotic symptoms at the end of treatment and follow-up.

Read the detailed description

Schizophrenia incidence peaks between 20 and 24 years, yet approximately one-third of cases manifest before age 18 as Early Onset Psychosis (EOP), which is associated with poorer outcomes compared to adult-onset cases, as reported in most of the literature. Psychoses are among the most severe disorders in children and adolescents (CAD), representing the second leading cause of years lost due to disability worldwide. Evidence suggests that early intervention in psychosis may improve outcomes, and there is increasing consensus among clinicians to initiate treatment as soon as sustained positive psychotic symptoms emerge. Within this early intervention framework, there is a strong hypothesis that intervening during the clinical high risk for psychosis (CHR-P) phase may mitigate, delay, or even prevent the onset of a full psychotic disorder. Reflecting these specific needs, the EPA guidelines recommend psychotherapeutic interventions as the first-line treatment for CHR-P conditions. Despite progress in early identification of psychosis risk states, advancements in psychotherapeutic interventions targeting the so-called "psychosis prodrome" remain limited. Importantly, existing interventions often fall short in addressing predictors of functional outcomes in the long term. Recent psychological, clinical, and neuroscientific studies underscore that socio-emotional difficulties are critical determinants of clinical and functional outcomes in CHR-P individuals. Furthermore, research in social cognition has highlighted that mentalization abilities, which continue to develop through adolescence and into adulthood, depend on complex cerebral connectivity to support functions such as mentalizing, perspective-taking, and moral judgment. These mentalizing processes are fundamental to adult social adaptation and have been shown to play a crucial role in maintaining good mental health. Mentalization-Based Treatment (MBT), a highly effective psychotherapeutic model for addressing socio-emotional difficulties, has been recently adapted for youth at clinical high risk for psychosis.

03

Conditions studied

  • Psychosis

Browse trials for

Keywords

  • Psychosis
  • MBT
  • Mentalization-Based Treatment
04

Who can participate

Ages eligible
14 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 14-30 years with a CHR-P condition, as defined by the SIPS criteria
  • Patients who provide

Exclusion criteria

Exclusion Criteria:

  • Patients with a prior diagnosis of a psychotic disorder
  • Intellectual disability (IQ \< 70).
  • Patients whose psychotic symptoms are primarily induced by substance misuse.
  • Patients with significant language barriers
  • Parents/legal authority who do not provide (only minors)
  • Adult patient under guardianship

Note: Comorbidities with other psychiatric disorders (e.g., Autism Spectrum Disorder, Personality Disorders) will not constitute an exclusion criterion.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
212 participants (estimated)

Study arms

  • No intervention
    NBCI

    Control intervention will consist of Need-Based Clinical Intervention (NBCI). NBCI reflects routine, community-based mental health services as delivered in real-world clinical settings. NBCI are not protocol-driven or manualized. Instead, following a structured baseline assessment of risk and clinical needs, treatment recommendations are formulated in accordance with internationally recognized clinical guidelines. A referral mental health professional, not involved in this study, is expected to conduct an initial assessment of each patient's personal needs. These interventions will be tailored according to these needs which will determine the type of treatments and theirs frequencies. These interventions include a large range of treatments such as pharmacological treatment, psychotherapeutic sessions (including psychoeducation), case management, or occupational support, delivered by patient's usual therapists, who are fully qualified mental health professionals.

  • Experimental
    MBT + NBCI

    Description: The MBT intervention consists of 24 weekly individual psychotherapy sessions, supplemented by monthly mentalization-based family therapy sessions spread across six phases. The individual sessions are manualized into six blocks, each comprising four weekly sessions. Each block typically begins with sessions that heavily incorporate psychoeducation and progressively transitions to a thematically guided session format. Both patient and family sessions will last 50 minutes, and may be audiotaped for quality control and intern supervision. Participants, along with their families or carers, will be informed of this procedure and retain the right to decline recording. Overall, the program is designed to improve patients' capacity to understand their own and others' mental states and, within interpersonal settings, how these patterns contribute to conflict and psychological distress.

    Other: MBT + NBCI

Interventions

  • OtherMBT + NBCI

    The MBT for CHR-P intervention consists of 24 weekly individual psychotherapy sessions, supplemented by monthly mentalization-based family therapy sessions. Both patient and family sessions will last 50 minutes. These psychotherapeutic sessions will complement those received though NBCI by strengthening mentalizing abilities aiming to reduce or prevent detrimental outcomes, by prohibiting or restricting some usual techniques in NBCI treatment (e.g., interpretation, cognitive challenge and Socratic dialogue) and by emphasizing certain techniques (e.g., empathic validation, active management of emotional arousal) which are only sporadically and irregularly used during NBCI treatment. Overall, the program is designed to improve patients' capacity to understand their own and others' mental states and, within interpersonal settings, how these patterns contribute to conflict and psychological distress.

06

What researchers measure

Primary outcomes

  1. SIPS

    All primary outcomes will be assessed at baseline (T0) during routine evaluation, end of treatment (T2; 24 weeks), and at 48 weeks follow-up (T3). The primary outcome of this study is the incidence of transition to psychosis within 6 months post-intervention, as measured by the Structured Interview for Psychosis-Risk Syndromes (SIPS). The SIPS is a well-validated, interview-based tool designed to assess symptoms, functioning, and diagnostic criteria for prodromal or at-risk mental states indicative of psychosis. Transition to psychosis, as well as remission from CHR-P state, will be determined based on predefined criteria within the SIPS framework. SIPS: Structured Interview for Prodromal Symptoms. Subscales scores (0 to 30). High score = More and/or severe psychotic symptoms

    Time frame: At Baseline (T0), at both end of treatment T2 : 24 weeks and at T3 : 48 weeks follow up evaluation

Secondary outcomes

  1. MentS

    The sub-hypotheses associated with Hypothesis 2 will be assessed using the Mentalization Scale (MentS), which measures three subdomains of mentalizing: self-mentalizing (SM), other-mentalizing (OM), and motivation to mentalize (MM). We will examine both the MentS total score and the three subscale scores independently to test the respective sub-hypotheses. MentS: Mentalization Scale. Total score (28 to 140). High score = Better mentalization skills

    Time frame: evaluated at baseline (T0), mid-treatment (T1: 12 weeks), end of treatment (T2: 24 weeks), and at the T3 (48 weeks follow-up).

  2. ETMCQ

    The sub-hypotheses associated with Hypothesis 3 will be evaluated using the Epistemic Trust, Mistrust, and Credulity Questionnaire (ETMCQ), which includes three subdomains of epistemic trust: trust, mistrust, and credulity. We aim to test the hypotheses using each of the ETMCQ subscale scores separately. ETMCQ: Epistemic Trust, Mistrust, and Credulity Questionnaire Subscales scores (5 to 35). "High ""Trust"" score = stronger functional stance of trust High ""Mistrust"" score = stronger maladaptive stances of mistrust High ""Credulity"" score = stronger maladaptive stances of credulity"

    Time frame: evaluated at baseline (T0), mid-treatment (T1: 12 weeks), end of treatment (T2: 24 weeks), and at the T3 (48 weeks follow-up).

  3. GAF

    The sub-hypotheses associated with Hypothesis 4 will be examined using the Global Assessment of Functioning (GAF) scale. This measure is included as part of the SIPS assessment to provide a single-item measure assessing overall psychosocial impairment due to mental health factors. GAF scale score ranges 0-100. High score = better functionning.

    Time frame: evaluated at baseline (T0), end of treatment (T2: 24 weeks), and at the T3 (48 weeks follow-up).

  4. GF-R

    The sub-hypotheses associated with Hypothesis 4 will be examined using the Global Assessment of Functioning - Role (GF-R) scale. This measure is included as part of the SIPS assessment to provide a single-item measure of role functioning. GF-R: Global Functioning - Role scale score ranges from 0 to10. High score = better functionning

    Time frame: evaluated at baseline (T0), end of treatment (T2: 24 weeks), and at the T3 (48 weeks follow-up).

  5. GF-S

    The sub-hypotheses associed with Hypothesis 4 will be examined using the Global Assessment of Functioning - Social (GF-S) scale. This measure is included as part of the SIPS assessment to provide a single-item measure of social functioning. GF-S: Global Functioning - Social scale ranges from 0 to10. High score = better functionning

    Time frame: evaluated at baseline (T0), end of treatment (T2:24 weeks) and at T3 (48 weeks follow-up)

  6. MADRS

    The sub-hypotheses associated with Hypothesis 5 will be assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) 10 items Sum of each item (0 to 60) High score = more severe depressive symptoms

    Time frame: evaluated at baseline (T0), mid-treatment (T1: 12 weeks), end of treatment (T2: 24 weeks), and at the T3 (48 weeks follow-up).

  7. OASIS

    The sub-hypotheses associated with Hypothesis 5 will be assessed using the Overall Anxiety Severity and Impairment Scale (OASIS). 5 item, Sum of each item (0 to 20) High score = more severe anxiety symptoms

    Time frame: evaluated at baseline (T0), end of treatment (T2: 24 weeks), and at the T3 (48 weeks follow-up)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Aug 2028, 36 months after the start.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 36 months is close to that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Jul 30, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2028
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07093671
Lead sponsor
Marco Armando
Responsible party
Marco Armando (PR, Centre Hospitalier Universitaire Vaudois) — Sponsor-investigator
First posted
Jul 30, 2025
Start date
Aug 1, 2025
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Jul 8, 2026

Study contacts

Marco Armando, Pr
Contact
marco.armando@chuv.ch
+41 079 556 49 46
Marco Armando, PR
principal investigator · Centre Hospitalier Universitaire Vaudois

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion